Collectively, our results indicate that MDSC-derived miR-155-5p drives HR + breast cancer progression by suppressing SIRT1, and our engineered TME-responsive polymeric micelle system effectively addresses key pharmacological barriers to synergistic cancer treatment. Here, SIRT1 is linked to breast carcinoma.